Efficacy of levofloxacin in the treatment of community-acquired pneumonia;Eficacia del levofloxacino en el tratamiento de neumonía adquirida en la comunidad

Medicina Interna de Mexico

Volumn 29, Issue 6, 2013, Pages 587-594

  López Véjar, César Emmanuel ^a   Castellanos De La Cruz, Lizbeth ^a   Meraz Ortega, Raúl ^a   Román Flores, Ariana ^a   Geuguer Chávez, Lizbeth ^a   Pedro González, Alejandra ^a   Lozano Nuevo, José Juan ^a   Rubio Guerra, Alberto ^a  

^a SECRETARÍA DE SALUD   (Mexico)

Author keywords

Ceftriaxone; Clarithromycin; Levofloxacin; Pneumonia

Indexed keywords

CEFTRIAXONE; CLARITHROMYCIN; LEVOFLOXACIN;

ALCOHOLISM; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HOSPITALIZATION; HUMAN; MEXICO; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SAMPLE SIZE; TREATMENT RESPONSE;

EID: 84892159089     PISSN: 01864866     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ERS Task Force in Collaboration with ESCMID. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-1180.
2. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009;374:1543-1556.
3. File TM, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997:1965-1972.
4. Querol-Ribelles JM, Tenías JM, Querol-Borrás M. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005;25:75-83.
5. Weyers CM, Leeper KV. Non-resolving pneumonia. Clin Chest Med 2005;26:143-158.
6. Xin Ye, et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: A retrospective claims database analysis. Clin Ther 2008;30.
7. Marrie TJ, Lau CY, Wheeler SL, Wong CJ. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000;283:749-755.
8. Shorr AF, et al. Levofloxacin 750 mg for 5 days for the treatment of hospitalized fine risk class III/IV community-acquired pneumonia patients. Respiratory Medicine 2006;100:2129-2136.
9. Klugman KP. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. Int J Antimicrob Agents 2004;24:411-422.
10. Short AE. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged >65 years with community-acquired pneumonia. Clin Ther 2005;27:1251-1259.
11. File TM, Tan JS. International guidelines for the treatment of community acquired pneumonia in adults: The role of macrolides. Drugs 2003;63:181-205.
12. Reinert RR, Hoban DJ, Felmingham D, Pluim J. World surveillance of antibiotic resistance among clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes during 1999/2000. Antimicrob Agents Chemother 2001;41:692.
13. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 2005;11:802-807.
14. Bergallo C, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Micr Infect Dis 2009;63:52-61.
15. Frank E. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24:1292-1308.
16. Gotfried MH, et al. A controlled, double-blind, muiticenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2004;24:736-751.
17. Barberá J, Martí B, García M, Escudero López-Cepero E. Azithtomicyn plus ceftriaxona versus levofloxacino in the treatment of hospitalized-patients with community acquired-pneumonia in Spain. A cost-minimization analysis. Value in Health 2007;10:A444.
18. Lloyd AC, Hoi AJ. A cost-minimization analysis comparing moxifloxacin versus levofloxacin and ceftriaxone for the treatment of patients hospitalized with community-acquired pneumonia: results from The MOTIVTRIAL. Value in Health 2007;10:A307.
19. Davydov L, et al. Prospective evaluation of the treatment end outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals. Diagn Micr Infect Dis 2006;54:267-275.